Molecular Profile |
Indication/Tumor Type |
Response Type |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
BRCA2 mutant
|
Advanced Solid Tumor
|
predicted - sensitive |
CX-5461
|
Phase I |
Actionable |
In a Phase I trial, CX-5461 treatment resulted in partial response in a patient with advanced solid tumor harboring BRCA2 mutations, and stable disease in 5 additional patients, 4 of whom harboring BRCA1/2 mutations, and 1 with Li-Fraumeni syndrome (Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 440; NCT02719977).
|
detail...
|
PTEN loss
|
prostate cancer
|
no benefit |
CX-5461
|
Preclinical |
Actionable |
In a preclinical study, CX-5461 treatment did not result in histological change in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174).
|
27486174
|
BRCA1 mutant
|
Advanced Solid Tumor
|
predicted - sensitive |
CX-5461
|
Phase I |
Actionable |
In a Phase I trial, CX-5461 treatment resulted in partial response in a patient with advanced solid tumor harboring BRCA2 mutations, and stable disease in 5 additional patients, 4 of whom harboring BRCA1/2 mutations, and 1 with Li-Fraumeni syndrome (Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 440; NCT02719977).
|
detail...
|